DOCSLIB.ORG

Tariffa Integrata Delle Comunità Europee (TARIC) Volume IV — Allegati (96/C 98 A/01 )

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

1 . 4 . 96 | IT I Gazzetta ufficiale delle Comunità europee 3101 I (Comunicazioni) COMMISSIONE Tariffa integrata delle Comunità europee (TARIC) Volume IV — Allegati (96/C 98 A/01 ) SOMMARIO Pagina Allegato 1 : Codici addizionali per gli elementi agricoli , codici addizionali e dazi addizionali sullo zucchero e sulla farina e prezzi di riferimento pesci 3103 Allegato 2: Elenco delle sostanze farmaceutiche 3169 Allegato 3 : CITES 3277 1 . 4 . 96 [ IT Gazzetta ufficiale delle Comunità europee 3103 ALLEGATO 1 — CODICI ADDIZIONALI PER GLI ELEMENTI AGRICOLI — CODICI ADDIZIONALI E DAZI ADDIZIONALI SULLO ZUCCHERO E SULLA FARINA — PREZZI DI RIFERIMENTO PESCI 3104 IT Gazzetta ufficiale delle Comunità europee 1 . 4. 96 CODICI ADDIZIONALI PER TABELLA DEI CAPI Codice di composizione (codice addizionale) di ta > 0<5 Materie grasse provenienti Proteine del latte Codice NC dal latte (% in peso) (% in peso) C ) > 0 >5 > 30 > 50 > 70 <5 < 30 < 50 < 70 0405 20 10 1905 30 11 > 0 < 1 ,5 > 0 < 2,5 7000 7001 7002 7003 7004 0405 20 30 1905 30 19 > 2,5 < 6 7020 7021 7022 7023 7024 1905 30 30 > 6 < 1 8 7040 7041 7042 7043 7044 1704 90 51 1905 30 51 > 18<30 7060 7061 7062 7063 7064 1704 90 55 1905 30 59 > 30 < 60 7080 7081 7082 7083 7084 1704 90 61 1905 30 91 > 60 7800 7801 7802 x x 1704 90 65 1905 30 99 1704 90 71 1905 40 10 > 1,5 <3 > 0 < 2,5 7100 7101 7102 7103 7104 1704 90 75 1905 40 90 > 2,5 < 6 7120 7121 7122 7123 7124 1704 90 81 1905 90 30 >6 < 18 7140 7141 7142 7143 7144 1704 90 99 1905 90 40 > 18 < 30 7160 7161 7162 7163 7164 1905 90 45 > 30 < 60 7180 7181 7182 7183 x 1806 20 10 1905 90 55 > 60 7820 7821 7822 x x 1806 20 30 1905 90 60 1806 20 50 1905 90 90 > 3<6 7840 7841 7842 7843 1806 20 70 > 0 < 2,5 7844 7200 7201 7202 7203 7204 1806 20 80 2004 10 91 > 2,5 < 1 2 > 12 7260 7261 7262 7263 7264 1806 20 95 2005 20 10 1806 31 00 1806 32 10 2101 1298 > 6<9 >0 <4 7860 7861 7862 7863 7864 1806 32 90 2101 20 98 > 4 < 15 7300 7301 7302 7303 7304 1806 90 11 2106 10 80 > 15 7360 7361 7362 7363 7364 1806 90 19 2106 90 98 1806 90 31 >9 < 12 > 0<6 7900 7901 7902 7903 7904 1806 90 39 >6 < 18 7400 7401 7402 7403 7404 1806 90 50 > 18 7460 7461 7462 7463 7464 1806 90 60 1806 90 70 > 12<18 > 0<6 7940 7941 7942 7943 7944 1806 90 90 > 6 < 1 8 7500 7501 7502 7503 7504 > 18 7560 7561 7562 7563 7564 1901 10 00 1901 20 00 1901 90 99 > 1 8 < 26 >0 < 6 7960 7961 7962 7963 7964 >6 7600 7601 7602 7603 7604 1904 20 10 > 26 < 40 >0 < 6 7980 7981 7982 7983 7984 >6 7700 7701 7702 7703 x > 40 < 55 7720 7721 7722 7723 x > 55 < 70 7740 7741 7742 x x > 70 < 85 7760 7761 7762 x x > 85 7780 7781 x x x (') Le caseine e/o i caseinati presenti nella composizione del prodotto non sono considerati proteine del latte se il prodotto non contiene altri compo­ nenti di origine lattica . 11 grasso butirrico contenuto nel prodotto in tenore inferiore a 1 % e il lattosio in tenore inferiore al 1 % , in peso, non sono considerati come altri componenti di origine lattica . Al momento dell'espletamento delle formalità doganali, l'interessato è tenuto ad indicare, nella dichiarazione prevista a tal fine : « solo ingrediente lattico : caseina/caseinato », se del caso . (2) Il tenore in amido o fecola della merce (allo stato in cui si trova), i suoi prodotti di degradazione — compresi tutti i polimeri del glucosio — e il glucosio eventualmente presente, determinati come glucosio ed espressi in amido (sostanza secca, purezza 100 % ; fattore di conversione del glucosio in amido : 0,9). Nel caso in cui venga dichiarata (in qualsiasi forma) e/o determinata nella merce una miscela di glucosio e di fruttosio, ai fini di tale calcolo il glucosio verrà preso in considerazione soltanto per la percentuale eccedente la quantità di fruttosio . C) Il tenore in saccarosio della merce (allo stato in cui si trova), addizionato del saccarosio risultante dal calcolo in saccarosio di qualsiasi miscela di glucosio o fruttosio (somma aritmetica delle quantità dei due zuccheri multiplicata per 0,95) che viene dichiarata (in qualsiasi forma) e/o determinata nella merce . Però, se il fruttosio è presente in quantità inferiore a quella del glucosio, quest'ultimo è considerato nel calcolo di cui sopra sino ad un valore in peso pari al tenore in fruttosio . NB: In ogni caso e quando sia dichiarata la presenza di un idrolizzato del lattosio e/o venga determinata fra gli zuccheri una quantità di galattosio, prima di effettuare qualsiasi calcolo si detrae dalla quantità totale di glucosio quella equivalente al galattosio . 1 . 4 . 96 IT Gazzetta ufficiale delle Comunità europee 3105 GLI ELEMENTI AGRICOLI TOH 14-17-18-19-20-21 lune merci di cui al regolamento (CE) n. 3448/93 Amido-Fecola / Glucosio (% in peso) (2) >5 < 25 > 25 < 50 > 50 < 75 > 75 Saccarosio / Zucchero invertito / Isoglucosio (% in peso)(3) >0 >5 > 30 > 50 >0 >5 > 30 >0 >5 >0 > 70 > 50 > 30 >5 <5 < 30 < 50 < 70 <5 < 30 < 50 <5 < 30 <5 7005 7006 7007 7008 7009 7010 7011 7012 7013 7015 7016 7017 7758 7759 7025 7026 7027 7028 7029 7030 7031 7032 7033 7035 7036 7037 7768 7769 7045 7046 7047 7048 7049 7050 7051 7052 7053 7055 7056 7057 7778 7779 7065 7066 7067 7068 7069 7070 7071 7072 7073 7075 7076 7077 7788 7789 7085 7086 7087 7088 x 7090 7091 7092 x 7095 7096 x x x 7805 7806 7807 x x 7810 7811 x x x x x x x 7105 7106 7107 7108 7109 7110 7111 7112 7113 7115 7116 7117 7798 7799 7125 7126 7127 7128 7129 7130 7131 7132 7133 7135 7136 7137 7808 7809 7145 7146 7147 7148 7149 7150 7151 7152 7153 7155 7156 7157 7818 7819 7165 7166 7167 7168 7169 7170 7171 7172 7173 7175 7 176 7177 7828 7829 7185 7186 7187 7188 x 7190 7191 7192 x 7195 7196 x x x 7825 7826 7827 x x 7830 7831 x x x x x x x 7845 7846 7847 7848 7849 7850 7851 7852 7853 7855 7856 7857 7858 7859 7205 7206 7207 7208 7209 7210 7211 7212 7213 7215 7216 7217 7220 7221 7265 7266 7267 7268 7269 7270 7271 7272 7273 7275 7276 x 7838 x 7865 7866 7867 7868 7869 7870 7871 7872 7873 7875 7876 7877 7878 7879 7305 7306 7307 7308 7309 7310 7311 7312 7313 7315 7316 7317 7320 7321 7365 7366 7367 7368 7369 7370 7371 7372 7373 7375 7376 x 7378 x 7905 7906 7907 7908 7909 7910 7911 7912 7913 7915 7916 7917 7918 7919 7405 7406 7407 7408 7409 7410 7411 7412 7413 7415 7416 7417 7420 7421 7465 7466 7467 7468 x 7470 7471 7472 x 7475 7476 x x x 7945 7946 7947 7948 7949 7950 7951 7952 7953 7955 7956 7957 7958 7959 7505 7506 7507 7508 7509 7510 7511 7512 7513 7515 7516 7517 7520 7521 7565 7566 7567 7568 x 7570 7571 7572 x 7575 7576 x x x 7965 7966 7967 7968 7969 7970 7971 7972 7973 7975 7976 7977 7978 7979 7605 7606 7607 7608 7609 7610 7611 7612 7613 7615 7616 x 7620 x 7985 7986 7987 7988 x 7990 7991 7992 x 7995 7996 x x x 7705 7706 7707 7708 x 7710 7711 7712 x 7715 7716 x x x 7725 7726 7727 7728 x 7730 7731 7732 x 7735 7736 x x x 7745 7746 7747 x x 7750 7751 x x x x x x x 7765 7766 x x x 7770 7771 x x x x x x x 7785 7786 x x x x x x x x x x x x 3106 I IT Gazzetta ufficiale delle Comunità europee 1 . 4. 96 CODICI ADDIZIONALI E DAZI ADDIZIONALI SULLO ZUCCHERO E SULLA FARINA ERGA OMNES-CEE EA AD S/Z AD F/M EA AD S/Z AD F/M Codice Codice addizionale addizionale Ecum/ 100 kg/net Ecum/ 100 kg/net Ecum/ 100 kg/net Ecum/ 100 kg/net Ecum/ 100 kg/net Ecum/ 100 kg/net 7000 0 0 0 7060 107.67 0 0 7001 12.16 12.16 0 7061 119.82 12.16 0 7002 22.8 22.8 0 7062 130.46 22.8 0 7003 32.93 32.93 0 7063 130.63 32.93 0 7004 47.12 47.12 0 7064 151.8 47.12 0 7005 6.11 0 6.11 7065 113.77 0 6.11 7006 18.27 12.16 6.11 7066 125.93 12.16 6.11 7007 28.9 22.8 6.11 7067 136.56 22.8 6.11 7008 39.03 32.93 6.11 7068 143.72 32.93 6.11 7009 53.22 47.12 6.11 7069 157.91 47.12 6.11 7010 13.05 0 13.05 7070 120.71 0 13.05 7011 25.21 12.16 13.05 7071 132.88 12.16 13.05 7012 35.84 22.8 13.05 7072 143.5 22.8 13.05 7013 45.98 32.93 13.05 7073 150.68 32.93 13.05 7015 20.54 0 20.54 7075 125.24 0 20.54 7016 32.7 12.16 20.54 7076 137.4 12.16 20.54 7017 43.34 22.8 20.54 7077 148.02 22.8 20.54 7020 20.1 0 0 7080 209.58 0 0 7021 32.26 12.16 0 7081 221.74 12.16 0 7022 42.89 22.8 0 7082 232.39 22.8 0 7023 52.48 32.93 0 7083 236.73 32.93 0 7024 66.66 47.12 0 7084 250.91 47.12 0 7025 26.21 0 6.11 7085 215.69 0 6.11 7026 38.37 12.16 6.11 7086 227.84 12.16 6.11 7027 49 22.8 6.11 7087 238.48 22.8 6.11 7028 58.58 32.93 6.11 7088 242.84 32.93 6.11 7029 72.77 47.12 6.11 7090 222.62 0 13.05 7030 33.14 0 13.05 7091 234.81 12.16 13.05 7031 45.3 12.16 13.05 7092 245.43 22.8 13.05 7032 55.94 22.8 13.05 7095 224.34 0 20.54 7033 65.52 32.93 13.05 7096 236.51 12.16 20.54 7035 40.08 0 20.54 7100 8.36 0 0 7036 52.24 12.16 20.54 7101 20.51 12.16 0 7037 62.89 22.8 20.54 7102 31.15 22.8 0 7040 60.29 0 0 7103 41.28 32.93 0 7041 72.45 12.16 0 7104 55.47 47.12 0 7042 83.08 22.8 0 7105 14.46 0 6.11 7043 91.56 32.93 0 7106 26.62 12.16 6.11 7044 105.74 47.12 0 7107 37.26 22.8 6.11 7045 66.4 0 6.11 7108 47.39 32.93 6.11 7046 78.56 12.16 6.11 7109 61.57 47.12 6.11 7047 89.19 22.8 6.11 7110 21.4 0 13.05 7048 97.66 32.93 6.11 7111 33.55 12.16 13.05 7049 111.85 47.12 6.11 7112 44.2 22.8 13.05 7050 73.34 0 13.05 7113 54.33 32.93 13.05 7051 8 5.5 12.16 13.05 7115 28.9 0 20.54 7052 96.13 22.8 13.05 7116 41.06 12.16 20.54 7053 104.6 32.93 13.05 7117 51.69 22.8 20.54 7055 79.17 0 20.54 7120 28.45 0 0 7056 91.34 12.16 20.54 7121 40.61 12.16 0 7057 101.97 22.8 20.54 7122 51.25 22.8 0 1 .
Recommended publications
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective

    Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective

    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
  • 付表 ⅠA 指定を受けた医薬の有効成分 Annex ⅠA Designated

    付表 ⅠA 指定を受けた医薬の有効成分 Annex ⅠA Designated

    付表ⅠA 指定を受けた医薬の有効成分 Annex ⅠA Designated Pharmaceutical Active Ingredients 号(Sub-heading) 品名 Description 2818.30 アルゲルドラート algeldrate 2833.22 アルスルフ alusulf 2842.10 アルマシラート almasilate 2842.10 シマルドラート simaldrate 2842.90 硫酸アルマドラ ート almadrate sulfate 2842.90 アルマガート almagate 2842.90 カルバルドラード carbaldrate 2842.90 ヒドロタルシト hydrotalcite 2842.90 マガルドラート magaldrate 2843.30 オーラノフィン auranofin 2843.30 金チオグリカニド aurothioglycanide 2843.30 金チオりんご酸ナトリウム sodium aurothiomalate 2843.30 金チオ硫酸ナトリウム sodium aurotiosulfate 2843.90 カルボプラチン carboplatin 2843.90 シスプラチン cisplatin 2843.90 デキソルマプラチン dexormaplatin 2843.90 エンロプラチン enloplatin 2843.90 イプロプラチン iproplatin 2843.90 ロバプラチン lobaplatin 2843.90 ミボプラチン miboplatin 2843.90 ネダプラチン nedaplatin 2843.90 オルマプラチン ormaplatin 2843.90 オキサリプラチン oxaliplatin 2843.90 セブリプラチン sebriplatin 2843.90 スピロプラチン spiroplatin 2843.90 ゼニプラチン zeniplatin 2844.40 アルツモマブ altumomab 2844.40 塩化セシウム(131Cs) cesium (131 Cs) chloride 2844.40 クロルメロドリン(197Hg) chlormerodrin (197 Hg) 2844.40 シアノコバラミン(57Co) cyanocobalamin (57 Co) 2844.40 シアノコバラミン(58Co) cyanocobalamin (58 Co) 2844.40 シアノコバラミン(60Co) cyanocobalamin (60 Co) 2844.40 エチオダイズド油(131I) ethiodized oil (131 I) 2844.40 くえん酸第二鉄(59Fe)注射液 ferric (59 Fe) citrate in 2844.40 フィブリノゲン(125I) fibrinogen (125 I) 2844.40 フルデオキシグルコー ス(18F) fludeoxyglucose ( 18 F) 2844.40 フルオロドパ(18F) fluorodopa (18 F) 2844.40 くえん酸ガリウム(67Ga) gallium (67 Ga) citrate 2844.40 金コロイド(198Au) gold (198 Au), colloidal 2844.40 イオベングアン(131I) iobenguane (131 I) 2844.40 よう化人血清アルブミン(125I) iodinated (125 I) human serum albumin 2844.40 よう化人血清アルブミン(131I) iodinated
  • Partial Agreement in the Social and Public Health Field

    Partial Agreement in the Social and Public Health Field

    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
  • General Agreement on Tariffs Andtrade

    General Agreement on Tariffs Andtrade

    RESTRICTED GENERAL AGREEMENT TAR/W/87/Rev.1 16 June 1994 ON TARIFFS AND TRADE Limited Distribution (94-1266) Committee on Tariff Concessions HARMONIZED COMMODITY DESCRIPTION AND CODING SYSTEM (Harmonized System) Classification of INN Substances Revision The following communication has been received from the Nomenclature and Classification Directorate of the Customs Co-operation Council in Brussels. On 25 May 1993, we sent you a list of the INN substances whose classification had been discussed and decided by the Harmonized System Committee. At the time, we informed you that the classification of two substances, clobenoside and meclofenoxate, would be decided later. Furthermore, for some of the chemicals given in that list, one of the contracting parties had entered a reservation and the Harmonized System Committee therefore reconsidered its earlier decision in those cases. I am therefore sending you herewith a revised complete list of the classification decisions of the INN substances. In this revised list, two substances have been added and the classifications of two have been revised as explained below: (a) Addition Classification of clobenoside, (subheading 2940.00) and meclofenoxate (subheading 2922.19). (b) Amendment Etafedrine and moxidentin have now been reclassified in subheadings 2939.40 and 2932.29 respectively. The list of INN substances reproduced hereafter is available only in English. TAR/W/87/Rev. 1 Page 2 Classification of INN Substances Agreed by the Harmonized System Committee in April 1993 Revision Description HS Code
  • The Organic Chemistry of Drug Synthesis

    The Organic Chemistry of Drug Synthesis

    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9